IOVANCE BIOTHERAPEUTICS, INC.
IOVAUnited States
69 filed reports · 592 financial concepts · 0 earnings calls · 0 media appearances
Filed reports
69 reports · Jun 2011 to Jun 2026Each report counts once it has at least one extracted financial fact. Also extracted from these reports: 24 guidance figures.
| Report type | Reports | Facts | Periods |
|---|---|---|---|
| Quarterly · 10-QSEC EDGAR | 44 | 5,056 | Sep 2011 to Jun 2026 |
| Annual · 10-KSEC EDGAR | 15 | 4,301 | Dec 2011 to Dec 2025 |
| Current · 8-KSEC EDGAR | 8 | 24 | Jun 2024 to Jun 2026 |
| Quarterly · 10-Q/ASEC EDGAR | 2 | 112 | Jun 2011 to Jun 2012 |
Documents
| Period | Type | Period end | Published | Facts | Source |
|---|---|---|---|---|---|
| FY2026 Q2 | 8-K | Jun 30, 2026 | Aug 6, 2026 | 2 | Open |
| FY2026 Q2 | 10-Q | Jun 30, 2026 | Aug 6, 2026 | 371 | Open |
| FY2026 Q1 | 8-K | Mar 31, 2026 | May 7, 2026 | 4 | Open |
| FY2026 Q1 | 10-Q | Mar 31, 2026 | May 7, 2026 | 258 | Open |
| FY2025 | 10-K | Dec 31, 2025 | Feb 24, 2026 | 769 | Open |
| FY2025 Q3 | 8-K | Sep 30, 2025 | Nov 6, 2025 | 2 | Open |
| FY2025 Q3 | 10-Q | Sep 30, 2025 | Nov 6, 2025 | 260 | Open |
| FY2025 Q2 | 10-Q | Jun 30, 2025 | Aug 7, 2025 | 164 | Open |
| FY2025 Q2 | 8-K | Jun 30, 2025 | Aug 7, 2025 | 2 | Open |
| FY2025 Q1 | 8-K | Mar 31, 2025 | May 8, 2025 | 2 | Open |
| FY2025 Q1 | 10-Q | Mar 31, 2025 | May 8, 2025 | 161 | Open |
| FY2024 Q4 | 8-K | Dec 31, 2024 | Feb 27, 2025 | 2 | Open |
Financial data
592 concepts · 9,493 factsEach concept is one reported line item or metric. The count is how many values of it are held, across the periods shown.
Financial575 concepts · 9,248 facts · Dec 2007 to Jul 2026
- Cash and cash equivalents at carrying value85 · Dec 2008 to Jun 2026
- Net income loss83 · Dec 2008 to Jun 2026
- Stockholders equity (US GAAP)83 · Dec 2007 to Jun 2026
- Operating income loss82 · Dec 2009 to Jun 2026
- Common stock shares issued79 · Dec 2010 to Jun 2026
- Payments to acquire property plant and equipment79 · Dec 2009 to Jun 2026
- Share based compensation79 · Dec 2009 to Jun 2026
- Accounts payable current78 · Dec 2010 to Jun 2026
- Assets78 · Dec 2010 to Jun 2026
- Assets current78 · Dec 2010 to Jun 2026
- Common stock par or stated value per share78 · Dec 2010 to Jun 2026
- Common stock shares authorized78 · Dec 2010 to Jun 2026
- Common stock shares outstanding78 · Dec 2010 to Jun 2026
- Common stock value78 · Dec 2010 to Jun 2026
- Liabilities and stockholders equity78 · Dec 2010 to Jun 2026
- Liabilities current78 · Dec 2010 to Jun 2026
- Property plant and equipment net78 · Dec 2010 to Jun 2026
- Research and development expense78 · Dec 2009 to Jun 2026
- Retained earnings accumulated deficit78 · Dec 2010 to Jun 2026
- Increase decrease in prepaid deferred expense and other assets77 · Mar 2011 to Jun 2026
- Net cash provided by used in operating activities75 · Dec 2009 to Jun 2026
- Prepaid expense and other assets current74 · Dec 2011 to Jun 2026
- Proceeds from issuance of common stock73 · Dec 2009 to Jun 2026
- Net cash provided by used in financing activities72 · Dec 2009 to Jun 2026
Segment14 concepts · 160 facts · Dec 2023 to Jun 2026
- Single reportable segment14 · Dec 2023 to Jun 2026
- Cost of revenue (US GAAP)13 · Dec 2023 to Jun 2026
- General and administrative expense (US GAAP)13 · Dec 2023 to Jun 2026
- Net income loss13 · Dec 2023 to Jun 2026
- Operating expenses (US GAAP)13 · Dec 2023 to Jun 2026
- Research and development expense13 · Dec 2023 to Jun 2026
- Revenue13 · Dec 2023 to Jun 2026
- Segment reporting other item amount13 · Dec 2023 to Jun 2026
- Selling and marketing expense (US GAAP)13 · Dec 2023 to Jun 2026
- Cost of goods and service excluding depreciation depletion and amortization11 · Dec 2023 to Jun 2026
- Depreciation and amortization11 · Dec 2023 to Jun 2026
- Royalty expense11 · Jun 2024 to Jun 2026
- Cost of goods and services sold (US GAAP)6 · Dec 2023 to Jun 2025
- Restructuring charges3 · Sep 2025 to Dec 2025
Geography1 concepts · 32 facts · Jun 2023 to Jun 2026
- Revenue32 · Jun 2023 to Jun 2026
Product1 concepts · 29 facts · Jun 2023 to Jun 2026
- Revenue29 · Jun 2023 to Jun 2026
Guidance1 concepts · 24 facts · Aug 2024 to Aug 2026
- Revenue Guidance24 · Aug 2024 to Aug 2026
Segments
221 factsFigures broken down by business line, region, product or another axis the company reports on.
Statement business segments1 member · 160 facts
- Single Reportable160 · Dec 2023 to Jun 2026
Statement geographical2 members · 32 facts
- Non Us16 · Jun 2023 to Jun 2026
- US16 · Jun 2023 to Jun 2026
Product or service3 members · 29 facts
- Proleukin16 · Jun 2023 to Jun 2026
- Amtagvi11 · Jun 2024 to Jun 2026
- Product2 · Jun 2023 to Sep 2023
Text from filings
Management commentary and risk factors, extracted from SEC filings only.
No commentary or risk-factor text for this company.
Earnings calls
Transcripts with management claims and analyst questions, one per fiscal period.
No earnings-call transcripts for this company.
Executive media
Podcasts, interviews and conference appearances by the company's executives, with their claims.
No media appearances for this company.
Reports are counted as filed reports with at least one served fact. Counts are read from the database (last read Oct 16, 2026) and refreshed every few hours.